Spotlight: Challenges and opportunities in the Dutch lock procedure: A national deep dive with a comparative European perspective on cell and gene therapy access

Despite numerous approvals from the European Medicines Agency (EMA), patient access to cell and gene therapies across Europe faces significant delays. On average, these therapies take 578 days to become available, according to the EFPIA W.A.I.T. indicator. In the Netherlands, the "lock procedure" treatments average around 600 days. Angela will present the results of a study comparing the number of reimbursed cell and gene indications in the Netherlands with those in select European countries, providing an analysis of reimbursement timelines and highlighting key Health Technology Assessment (HTA) challenges. Angela will conclude the presentation with potential solutions for advancing collaborative and sustainable initiatives to enhance patient access and invites the audience to join the discussion.